Concepedia

Publication | Closed Access

Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

DOI

424

Citations

0

References

1992

Year

Stephan L. Suter, John J. Nolan, Penny Wallace, Barry M. Gumbiner, Jerrold M. Olefsky
Diabetes Care

Abstract

CS-045 improves insulin resistance, reduces insulinemia, lowers hepatic glucose production, and improves both fasting and postprandial glycemia in NIDDM subjects. CS-045 may represent a new therapeutic option for NIDDM.